Stockscreener 앱 받기
292.90
2.57%
7.34
시간 외 거래:
293.00
0.10
+0.03%
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace
RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch By Investing.com - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch - Investing.com
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Alnylam supports LGBT community inside and outside the workplace - The Business Journals
3 High-Flying Stocks That Could Soar Even More - AOL.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Alnylam Issues 2024 Corporate Responsibility Report - BioSpace
Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus
Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
High Growth US Tech Stocks To Watch In May 2025 - simplywall.st
Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader
Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters
Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo
Alnylam shareholders approve executive compensation plan - Investing.com
Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks
12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey
Hypercholesterolemia Treatment Market Top Companies Study - openPR.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st
Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com
Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus
Alnylam to present key data on amyloidosis treatments - Investing.com Australia
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
Trend Tracker for (ALNY) - news.stocktradersdaily.com
‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review
RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN
Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com
Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com
0.82%
자본화:
|
볼륨(24시간):